See ACE-031 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
ACE-031 (ramatercept) is a soluble activin receptor type IIB-Fc fusion protein engineered to act as a myostatin trap, sequestering myostatin and related TGF-beta family ligands to permit muscle hypertrophy. Acceleron Pharma advanced it into Phase 2 trials in Duchenne muscular dystrophy that were halted on safety grounds. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with ACE-031.
ACE-031 (international name ramatercept) is a recombinant soluble activin receptor type IIB-Fc fusion protein developed by Acceleron Pharma as one of the first attempts to translate the long preclinical literature on myostatin-pathway inhibition into a human therapy. The molecule is engineered as a decoy receptor — the extracellular domain of the activin receptor IIB fused to an Fc fragment — that circulates and sequesters myostatin (GDF-8) and related TGF-beta family ligands (GDF-11, activin A, activin B) before they can engage their native cell-surface receptors. The therapeutic logic follows from the mouse and bovine genetic literature, in which loss-of-function mutations in the myostatin gene produce dramatic skeletal-muscle hypertrophy (the "double-muscled" Belgian Blue cattle and myostatin-knockout mice).
ACE-031 (ramatercept) is a recombinant ActRIIB-Fc fusion protein studied as a myostatin/activin decoy for muscle-wasting research; its clinical program was halted in 2011 over a vascular safety signal. It ships as a lyophilized protein, so vendor quality hinges on what the certificate of analysis (COA) shows for a large recombinant molecule.
Soluble extracellular ActRIIB-Fc binds and sequesters myostatin (GDF-8) and several related TGF-β-family ligands — activin A, activin B, and GDF-11 — preventing them from engaging full-length cell-surface ActRIIB and ActRIIA. The result in pre-clinical models is broad activin-pathway inhibition, larger muscle-mass gains than selective anti-myostatin antibodies, and a corresponding broader off-target profile because activin A and GDF-11 have important non-muscle physiological roles (vascular biology, haematopoiesis, reproductive endocrinology).
No regulatory approvals. , 2013) and Phase 2 in boys with Duchenne muscular dystrophy were the only registered human studies; the Duchenne programme was discontinued in 2011 and the broader development of the molecule was wound down. 3–3 mg/kg single intravenous or subcutaneous in healthy postmenopausal women, with the 3 mg/kg dose producing measurable serum-biomarker changes (increased thigh muscle volume on MRI, increased serum biomarkers of bone formation). No validated dose for non-trial use; the molecule was discontinued.
ACE-031 has a reported half-life of ~11 days, and the dose intervals researchers model most often fall around every 2–4 weeks. Very long-acting because it is an antibody-style fusion protein. Doses are spaced weeks apart and a large amount carries over from one dose to the next. It is catalogued under Muscle Peptides on WPA.
15 ACE-031 reconstitution calculations have been logged by the WPA community. The most common dose entered is 200mcg (4 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 1mg (8 sessions). The most common dosing frequency is once weekly (1 logged protocols).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.